Kornimate/medical-research-clean huggingface dataset:
is ejaculation preservation turis the natural evolution of the "gold standard".

Conditions: Benign Prostatic Hyperplasia

Summary: evaluation of the impact of apical urethral mucosa sparring with the urethra around the verumontanum on the ejaculatory function and early postoperative urinary incontinence

benign prostatic hyperplasia (bph) is a common disease in elderly men and transurethral resection of the prostate (turp) is still the gold standard for the treatment of bph however, postoperative urinary incontinence (ui) and retrograde ejaculation are of the common complications and its incidence is nearly 2% of ui ui brings great suffering to patients and its unpredictability and uncertainty in the recovery period cause significant pressure to surgeons. external urethral sphincter damage is the main reason for ui after prostatectomy. the treatment of postoperative ui and post operative retrograde ejaculation has also become an important issue for many years. along with the progress of technology, there have been various methods of transurethral resection of the prostate but no method has been found to adequately avoid the occurrence of ui and retrograde ejaculation

Eligibility criteria:
our inclusion criteria were preidentified to those who complained of voiding lower urinary tract symptoms (luts) and scheduled for turp with prostate size less than 100 gm. this included patients with refractory retention, recurrent gross hematuria of prostatic origin, non-compliance to medical treatment, recurrent infection, and patients with bladder calculi secondary to obstruction. exclusion criteria were: patients with neurogenic bladder, detrusor hypo-contractility, diabetes more than 10 years, urethral stricture, or previous prostatic surgeries.

Keywords: ejaculation, incontinence
china stroke secondary prevention trial

Conditions: Stroke; Transient Ischemic Attack

Summary: the csspt study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in china to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death.

the csspt study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in china to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death in patients with recent stroke or transient ischemic attack (tia). all patients presenting to one of the participating neurologists or general physicians within one months of stroke (ischemic or hemorrhagic) or tia (eye or brain) are eligible for this trial. eligible patients will be randomized in a double-blinded fashion to receive multi-vitamins or placebo. the primary outcome event is the composite event "stroke, myocardial infarction, or death from any vascular cause", whichever occurs first. our target is to recruit a total of 8,000 patients over the two years with a median follow-up of 3 years. recruitment to the trial began in july 2011 and is planned to continue until december 2013. the investigators aim to complete final follow-up by the end of 2016.

Eligibility criteria:
inclusion criteria: * patients presenting within one months of ischemic stroke (ischemic or hemorrhagic) or tia * homocysteine level ≥ 15μmol／l * agree to take study medication;be geographically accessible for follow-up * provide written informed consent exclusion criteria: * other cause of ischemic stroke (cardioembolism; stroke of other determined etiology, and stroke of undetermined etiology according to toast subtypes) or hemorrhagic stroke (intracranial vascular malformations; cerebral amyloid angiopathy; trauma and bleeding disorders etc) * use of vitamin supplements containing folate, b6 or b12 * pregnancy or women of child-bearing potential who are at risk of pregnancy * limited life expectancy

Keywords: folic acid b vitamins secondary prevention stroke randomized controlled trial homocysteine
lupus landmark study: a prospective registry and biorepository

Conditions: Systemic Lupus Erythematosus (SLE); Lupus Nephritis; Neuropsychiatric Systemic Lupus Erythematosus

Summary: the purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on systemic lupus erythematosus (sle), including lupus nephritis (ln).

this is a multicenter registry and biorepository conducted in the united states (us) and canada. the registry will enroll over 3500 individuals with sle over the course of five years into one of following four cohorts: * new onset: individuals with a new diagnosis of sle * active lupus nephritis: individuals with a recent diagnosis of ln * extra-renal lupus flare: individuals who have experienced a recent flare * prevalent cases: individuals with lupus who do not meet the criteria for one of the other cohorts the registry data will include but is not limited to: patient demographics, medical history, clinician-reported outcomes (clinros), patient-reported outcomes (pros), social history and determinants of health, and environmental exposures. participants will also be asked to allow access to their medical records. biological samples, including whole blood, urine, saliva, stool and tissue will be collected throughout the study. these biospecimens will be used for a broad range of analyses, including genetics, genomics, proteomics, biomarker discovery and microbiome profiling.

Eligibility criteria:
inclusion criteria: * able to understand and comply with study procedures and voluntarily sign a written informed consent document * age 18 years or older at the time of enrollment * fulfill criteria for sle based on one or more of the following classifications systems: systemic lupus erythematosus international collaborating clinic (slicc) 2012 criteria; european alliance of associations for rheumatology (eular)/american college of rheumatology (acr) 2019 criteria; 1997 revised acr criteria; or lupus is present per clinical assessment. exclusion criteria: * not able to obtain consent * not able to meet protocol visit requirements * pregnant at the time of enrollment
a clinical trial of soluble fiber for asthma

Conditions: Asthma in Children

Summary: randomized controlled trial of soluble fiber (novelosetm 3490). participants will complete an asa 24 dietary recall questionnaire to access their fiber intake. if eligible for the study, participants will be supplemented to their target fiber dosage with either soluble fiber (novelosetm 3490) or placebo. collection of blood serum, fecal samples, and nasal wash will aid in analyzing the microbes present in one's gut and how fiber and diet may impact it. thus, allowing researchers to better understand the pathways that may connect diet and asthma and if it is possible to improve asthma by altering one's diet.

a phase ii randomized, controlled, clinical trial analyzing the impact of increasing fiber intake and the gut microbiome for children with asthma. if eligible, (determined by inclusions/exclusion criteria as well as fiber intake assess by asa 24) participants will be put into a fiber (novelosetm 3490) or placebo (maltodextrin) group. each participant will fil out an asthma control questionnaire (acq), collect a nasal wash, and have their blood drawn. their study medication will be available for them to pick up after their first visit, and they will receive counseling from the pharmacist on how to implement it into their diet. they will also be sent home with three stool sample kits to be mailed to northern arizona university for microbiome analysis. the first kit will be sent within 7 days of their first visit. the second kit will be sent within 2-3 weeks of their first visit. the second study visit will occur 4-6 weeks after the first visit. all the procedures will be repeated again including taking the asa 24 questionnaire. the participant will send their final kit within 7 days of completing their last visit. total study time is 6 weeks. this study is minimal risk which includes risk of fecal contamination, discomfort from collecting specimens, discomfort with answering some of the survey questions, and the risks associated with receiving a blood draw. participants are compensated for their time and receive a portion of their dietary results. there may not be a direct benefit to the participant, but by participating in this research they may help people in the future with asthma.

Eligibility criteria:
inclusion criteria: * between ages 6-17 * asthma diagnosis within the last 2 years * fractional excretion of exhaled nitric oxide (feno) \> 50 ppb or a clinical history of environmental allergies as defined by a positive skin prick or positive specific immunoglobulin e (ige) tests to aeroallergens * no emergency department visits in the past 1 month * ability to consume a liquid drink of fiber or placebo * ability to return for a 4-6 week follow-up visit * no special or unique diet exclusion criteria: * cystic fibrosis * bronchiectasis * change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks * baseline estimated daily fiber intake less than or equal to 16 grams as determined by the asa 24 * sibling of a participant already enrolled in the study
mesotherapy in lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: investigate the short- and long-term efficacy and safety of intradermal nsaids and lidocaine (delivered through mesotherapy) for the treatment of le comparing it with empty intradermal injections.


Eligibility criteria:
inclusion criteria: * clinical diagnosis defined as pain over the lateral epicondyle provoked by palpation; * a visual analogue scale (vas) score for pain greater than 40mm; * symptoms duration for more than 1 month. exclusion criteria: * other diseases that can alter clinical evaluation detected through history, clinical examination, ultrasound or other exams for comorbidities such as carpal tunnel syndrome, cervical radiculopathy, elbow arthritis, intra-articular loose bodies, previous elbow surgery or clinically significant or recent trauma, fibromyalgia and major psychiatric conditions; * vas score for pain less than 40mm; * any of the following treatments during the previous 4 weeks before baseline visit: physical therapy, bandage, mesotherapy and local corticosteroid injection or a combination of these: nsaids taken during the week previous to inclusion; * pregnancy; * allergy to any of the study drugs; * severely immunosuppressed patients; * known coagulopathies. during the study period, enrolled patients are not allowed to take oral corticosteroids, nsaids or receive any other medical intervention during the treatment period (physical therapy, bandage, mesotherapy and local corticosteroid injection or a combination of these).
anakinra as a treatment for hydradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: this is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (hs). the planned intervention is to provide about 6 hs patients with anakinra 100mg daily injections to administer subcutaneously for 8 weeks. then, the study subjects will be followed for a further 8 weeks to monitor for relapse of hs.


Eligibility criteria:
inclusion criteria: 1) signed informed consent form with confirmed diagnosis of hidradenitis suppurativa with moderate or severe disease activity exclusion criteria: 1. use of the following therapies: * etanercept in the 4 weeks prior to the baseline visit (day 1) * adalimumab in the 8 weeks prior to the baseline visit (day 1) * infliximab in the 12 weeks prior to the baseline visit (day 1) * any other investigational biologics in the 8 weeks prior to the baseline visit (day 1) * leflunomide in the 4 weeks prior to the baseline visit (day 1) • thalidomide in the 4 weeks prior to the baseline visit (day 1) * cyclosporine in the 4 weeks prior to the baseline visit (day 1) * i.v. immunoglobulin (i.v. ig) in the 8 weeks prior to the baseline visit (day 1) * 6-mercaptopurine, azathioprine, cyclophosphamide, or chlorambucil in the 12 weeks prior to the baseline visit (day 1) * colchicine, dapsone, mycophenolate mofetil \& systemic antibiotics in the 3 weeks prior to the baseline visit (day 1) * corticosteroids "20mg/day or \>0.4 mg/kg, whichever applies, in the 1 week prior to the baseline visit (day 1) 2. history of immunocompromise including hiv infection 3. positive hep b surface antigen -

Keywords: hidradenitis suppurativa anakinra
a study to evaluate microvessel ultrasound imaging of wound healing in patients with chronic ulcers

Conditions: Non-Healing Ulcer of Skin; Non-healing Wound; Lower Extremity Wound

Summary: the purpose of this research is to explore the use of high-resolution microvessel ultrasound imaging system to look for scarring and to monitor wound healing and to see if treatment affects the amount of tiny vessels and circulation around the wound.


Eligibility criteria:
inclusion criteria: * chronic wound in the course of diabetic foot ulcers and/or lower extremity venous ulcers with duration of at least 6 weeks and the wound surface not less than 2 sq. cm and not greater than 15 sq. cm, without evidence of active infection of the wound at the time of qualification to participate in the study * meets criteria for stalled chronic wound defined as less than 50% reduction in wound size after 30 days of standard of care management. * for chronic venous ulcers, ultrasound demonstrates venous reflux \>0.5 seconds * satisfactory blood glucose control - fasting not more than 110 mg%, hba1c \<6.5% * satisfactory blood supply to the wound verified by the measurement of the oxygen level of the foot tissue (tcpo2 \> 30mmhg) in patients with neuropathic etiology of diabetic foot syndrome * in the case of the patients with the wounds of ischemic component, the condition for qualification is a clinical improvement of the limb's blood supply as a result of the revascularization procedure documented by ultrasound. * ankle-brachial index (abi) ≥ 0.8 exclusion criteria: * acute wound with duration less than 6 weeks * evidence of active infection or on antibiotics * smoker * for chronic venous ulcers, ultrasound demonstrates venous reflux \<0.5 seconds * unsatisfactory blood glucose control - fasting more than 110 mg%, hba1c \<6.5% * poor blood supply to the wound verified by the measurement of the oxygen level of the foot tissue (tcpo2 \< 30mmhg) in patients with neuropathic etiology of diabetic foot syndrome * ankle-brachial index (abi) \< 0. * pregnancy * known allergy to lidocaine
virtual reality for chronic pain and opioid use disorder pilot

Conditions: Chronic Pain; Opioid Use Disorder

Summary: this is a pilot feasibility study of a virtual reality device for patients with co-morbid chronic pain and opioid use disorder.

the investigators will conduct a study of patients with co-morbid chronic pain and opioid use disorder enrolled in a methadone maintenance treatment program (mmtp) to pilot device feasibility and measure changes in pain intensity and opioid craving. all patients will be randomized to one of each of the following arms: 1) relievrx (intervention group) or 2) non-immersive sham vr (control group). the intervention being piloted is the relievrx - appliedvr, los angeles, california - vr hardware and software. relievrx incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. relievrx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. relievrx was designed for at-home use and comes with a sequence of daily immersive experiences. relievrx is typically delivered in a 56-day program through daily virtual experiences, with each experience lasting between 2 and 16 minutes. in this pilot study, the investigators will conduct virtual experiences twice weekly at the mmtp. over 6 weeks, participants in both groups will participate in 20-30 minute vr sessions twice per week. each session will last about 20-30 minutes and go through 1-5 virtual experiences. the sham vr control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the relievrx. control participants will similarly experience 1-5 virtual experiences in each 20-30 session.

Eligibility criteria:
inclusion criteria: 1. ≥18 years old 2. english proficiency 3. receiving methadone treatment for dsm-5 (diagnostic and statistical manual of mental disorders, 5th edition) confirmed opioid use disorder (oud) in the montefiore network for at least 12 weeks, with no dose change in 14 days to ensure treatment stability 4. chronic pain of at least moderate pain severity (score ≥4 on the pain, enjoyment of life, and general activity (peg) scale) 5. willingness to participate in all study components 6. ability to provide informed consent, assessed using consent teach-back exclusion criteria: 1. conditions that could make participation in vr hazardous or cause adverse effects (current or prior diagnosis of epilepsy, seizure disorder, dementia, or migraines, any medical condition predisposing to nausea or dizziness, hypersensitivity to flashing light or motion) 2. conditions that could prevent proper use of the vr headset (stereoscopic vision or severe hearing impairment, or injury to eyes, face, or neck that prevents use of the vr headset) 3. acute exacerbation of psychiatric conditions that preclude the ability to participate in the study
weight-based enoxaparin dosing and real-time dose adjustment in orthopaedic trauma

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolus

Summary: the rates of venous thromboembolism (vte) after orthopedic surgery are as high as 40-60% without prophylactic measures. enoxaparin, a low-molecular-weight heparin, produces an anticoagulant effect by binding antithrombin, thereby accelerating antithrombin's inactivation of coagulation factor xa (fxa), thus decreasing the likelihood of clot formation. despite standard dosing enoxaparin prophylaxis, vte rates in post-operative orthopedic trauma patients remain as high as 12.2%.the investigators will examine enoxaparin pharmacokinetics and test whether a clinical protocol for real-time enoxaparin dose adjustment can favorably alter the proportion of patients with in-range anti-factor xa (afxa) levels. outcomes will include peak and trough steady-state afxa levels in response to standard and escalated doses of enoxaparin and the incidence of venous thromboembolism and bleeding events post-surgery. in the trauma and orthopaedic populations, patients with low initial afxa levels are significantly more likely to develop deep venous thrombosis. thus, this study has important implications for appropriate enoxaparin dose magnitude and frequency, and may ultimately help to decrease the substantial morbidity and mortality associated with post-operative vte.


Eligibility criteria:
inclusion criteria: * receiving orthopedic trauma surgery * able to have enoxaparin initiated within 36 hours after procedure exclusion criteria: * intracranial bleeding/stroke * bleeding disorder * heparin-induced thrombocytopenia * creatinine clearance \< 30 ml/minute * epidural catheter * serum creatinine \> 1.6 mg/dl
effects of monascus garlic fermented extract on serum triglyceride level

Conditions: Hypertriglyceridemias

Summary: the purpose of the study is to determine the effect of monascus garlic fermented extract on serum lipid concentrations in subjects with moderately elevated serum triglyceride.


Eligibility criteria:
inclusion criteria: * healthy as based on medical history and physical examination * fasting serum triglyceride 120 to 200mg/dl * willing not to serve as blood donor during the study * informed consent signed exclusion criteria: * female subjects who are pregnant or nursing a child * participation in any clinical trial up to 90 days before day 1 of this study * renal or hepatic dysfunction * heart disease * under medication * subjects who are taking functional food designed for weight loss or serum lipid reduction

Keywords: moderately elevated serum triglyceride
feasibility of eswt treatment in post-stroke patients with triceps sural spasticity

Conditions: Stroke

Summary: the main objective is to evaluate the feasibility of two different rehabilitation protocols that differed from the number of treatment sessions (1 session of eswt versus 3 weekly sessions of eswt), in patients with triceps surae spasticity after stroke. in both arms the other eswt parameters (types of eswt, intensity, frequency, location) and stretching sessions are the same. secondary objectives: to compare functional performances in these two groups of patients receiving the different rehabilitation protocol with eswt, using the following parameters: - six minutes walking test (6mwt) ; - time up \& go (tug); - modified ashworth scale (mas); - lower extremity functional scale (lefs); - passive ankle range of motion (p-rom), pain (nrs); and presence of ankle clonus. these parameters are assessed during baseline (t0), after 4 weeks (t1) and after 12 weeks (t2).


Eligibility criteria:
inclusion criteria: * adult patients of legal age * time elapsed since the stroke between 6 and 60 months * autonomous or supervised walking with or without aids * spasticity of the sural triceps\> 1 on the mas scale exclusion criteria: * joint stiffness of the lower limbs due to other pathologies (ex orthopedic or rheumatological); * conditions that interfere with evaluation or collaboration in rehabilitation treatment (major psychiatric illnesses, clearly detectable cognitive deficits, severe pre-existing disabilities, sensory disturbances, etc.) * focal antispasmodic toxin treatments in the previous 3 months or phenolic blocks in the previous 9 months in the treatment region * treatments with central antispasmodic drugs with dosage modifications in the last week of starting treatment * individual neurorehabilitation treatments in progress

Keywords: stroke triceps sural spasticity extracorporeal shockwave therapy